Overall verdict
Neutral
5.3/10
1-year performance
+61.78%
Score breakdown
Up 61.8% over 1 year, 87% of the 52-week range.
Strongest: Financial strength 6.5/10. Weakest: Growth 2.4/10.
28 analysts, target +0.1% vs the price.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands ; Allflex Livestock Intelligence solutions ;
and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates ;
AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types ; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova ; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Nyse
United States
CEO
Robert Davis
Founded
1891
Employees
75 000
Revenue / employee
865 680 USD
Next earnings
February 2, 2027 (Q4 2026)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.50%
- FMR LLC1.87%
- Bank of New York Mellon Corp0.74%
- Rest of the register94.89%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
156.92 USD
52-week low
87.26 USD
1-year performance
61.78%
Rising
Year-to-date performance
40.13%
Rising
Drawdown
-5.76%
Mild pullback
Position in the 52-week range
87% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned less, while shaking 1.6 times harder.
$10,000 placed at the end of December 2000 are worth today
| Merck | $40,704 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.6 times as much as the world ETF.
- Worst fall:-67 % between December 2000 and November 2004. $10,000 placed at the top fell to $3,303. The world ETF, at worst: -53 %. Back to its high in 112 months.
Merck earned less than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Merck: $40,704
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 23.09 USD - 94.59 USD (comparables only)
The price implies growth of 7.77% per year; the company grows at 21.23%.
Gross margin 71.4%, net margin 3.6%, ROIC 2.6%, ROE 5.1%.
Net margin
3.65%
Low
Sector 9.99%|S&P 13.40%
Gross margin
71.41%
High
Return on equity (ROE)
5.07%
Fair
Sector 6.74%|S&P 17.06%
Return on invested capital (ROIC)
2.63%
Low
Free cash flow margin (FCF)
21.93%
Exceptional
Profit-to-cash conversion (FCF conversion)
6.01x
Exceptional
Margin stability
9.3 pts
Uneven
Revenue to net income
Growth
2.4/10Revenue up 5.5% over 1 year, 9.3% a year over 5, EPS 21.2% a year over 5.
Revenue (trailing 12 months)
67.2Md USD
Revenue growth (1y)
5.47%
Solid
Revenue growth (3y)
11.04%
Moderate
EPS growth (1y)
-11.74%
Declining
EPS CAGR (5y)
21.23%
Exceptional
EPS revisions (3 months)
1.38%
Revised up
Valuation
2.6/10P/E 151.0x, forward P/E 105.0x, EV/EBITDA 20.9x, PEG 7.12. The multiple sits in the 75th percentile of its own 5-year history.
P/E (TTM)
151.0x
Very expensive
Sector 27.7x|S&P 23.6x
Forward P/E
105.0x
Very expensive
EV / EBITDA
20.9x
Expensive
Sector 14.2x|S&P 15.5x
PEG
7.12
Very expensive
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
58.84 USD
Deeply overvalued
P/E vs its own 5-year history
among the 25% highest valuations
Pricier than usual
Market cap
365Md USD
Financial strength
6.5/10Cash covers 18.1% of the debt, net debt/EBITDA 1.2x.
Net debt / EBITDA
1.2x
Solid
Gearing (net debt / equity)
97.95%
Tight
Cash
9.8Md USD
Cash / market cap
2.68%
Stretched
Cash / total debt
18.13%
Tight
Interest coverage
6.3x
Solid
Net debt
44.0Md USD
Equity
44.9Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 148.05 USD
- MM20146.30
- MM50146.37
- MM200128.05
- RSI 1453.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+3.18%
200-day average slope, 3 months
+12.99%
50-day average slope, 1 month
+1.81%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.18 % per day
Volatility change
+10.39%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 1.41 (10) | 2.78 (26) | 67 242 (25) | 15 783 (9) | 3 455 (8) |
| 2027 | 7.93 (10) | 8.98 (25) | 69 461 (25) | 31 780 (10) | 19 335 (8) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 9, 2026.
Same sub-industry: 503 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AZN | 7.1 | 7.0 | 286Md USD | 26.7x | 17.7 % | 7.1 % | 14.4 % | 1.2x | 3.6 % | 3.7 % | ||
| 2 | BMY | 6.6 | 6.9 | 129Md USD | 13.9x | 18.5 % | 7.0 % | 14.0 % | 1.9x | 7.2 % | 32.5 % | ||
| 3 | NOVO B | 6.2 | 7.7 | 178Md USD | 10.7x | 33.9 % | 5.6 % | 38.1 % | 0.7x | 6.0 % | -8.5 % | ||
| 4 | ROP | 6.2 | 6.4 | 385Md USD | 26.2x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 4.7 % | 42.5 % | ||
| 5 | NOVN | 6.1 | 6.5 | 295Md USD | 32.0x | 18.0 % | 6.0 % | 13.5 % | 1.0x | 5.0 % | 29.2 % | ||
| 6 | LLY | 6.0 | 5.1 | 1.4T USD | 47.2x | 31.9 % | 38.6 % | 36.3 % | 1.2x | 1.5 % | 48.7 % | ||
| 7 | JNJ | 5.6 | 5.2 | 675Md USD | 42.5x | 16.2 % | 5.9 % | 13.6 % | 0.9x | 3.1 % | 48.1 % | ||
| 8 | MRK | 5.3 | 3.6 | 365Md USD | 151.0x | 3.6 % | 5.5 % | 2.6 % | 1.2x | 4.0 % | 61.8 % | ||
| 9 | PFE | 5.2 | 4.6 | 168Md USD | 42.1x | 6.3 % | -0.4 % | 2.7 % | 2.3x | 7.0 % | 20.3 % |
